LSP1 and acute myeloid leukemia: found, based on the analysis of TCGA data, that the IC50 of sorafenib in the high LSP1 group was significantly lower than that in the low LSP1 group, indicating that LSP1 in AML patients was significantly negatively correlated with sorafenib sensitivity.